Biogen Inc. (BIIB)
Biogen is a Cambridge, Massachusetts biopharmaceutical company that develops and sells medicines for neurology and rare diseases. It last closed at $250.79 on Nov 17, down 0.34% on the day. BIIB reports earnings on Fri, Feb 5, 2027. The average 12-month price target from 17 analysts is $273.29 (+9.0% from the last close), with a high of $310.00 and a low of $225.00. Analyst consensus is Strong Buy, based on the latest ratings from 17 firms (13 buy, 4 hold, 0 sell). Over the past 90 days StreetAlpha recorded 4 whale options trades in BIIB, 25% of them bullish and 75% bearish. In the past 30 days there were 4 dark pool prints totaling $3.3M, the largest $1.1M.
Key Stats
Last 12 monthsNot reported for this period.
From BIIB's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 28). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 17 analysts who set a price target on BIIB in the past 90 days. The average target is $273.29, with a high of $310.00 and a low of $225.00, compared with the last close of $250.79.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 9 | Piper Sandler | Target raised | Buy | $245 → $305 |
| Nov 2 | Guggenheim | Maintained | Buy | $300 |
| Nov 2 | HC Wainwright & Co. | Maintained | Buy | $270 |
| Oct 29 | Canaccord Genuity | Target raised | Buy | $248 → $272 |
| Oct 29 | Argus Research | Upgrade | Buy | $280 |
Technical Analysis
The stock is 0% above its 20 day and 6% above its 50 day average. It is 18% above its 200 day average, so the longer trend is still up. Momentum is neutral (RSI 56). The nearest support is the Pivot at $250.59, and the nearest resistance the Pivot R1 at $252.92.
| RSI (14) | 56.04 | Middle of its range | Neutral |
| MACD | 4.90 | Below its signal line | Bearish |
| Stochastic | 56.9 | Middle of its range | Neutral |
| ADX (14) | 26.7 | Trending up | |
| Williams %R | -48.6 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -0.1 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +0.8% | Change over 10 sessions | Bullish |
| ATR (14) | $7.29 | Typical daily range, 2.9% of price |
| RSI (14) | 69.71 | Strong, overbought above 70 | Neutral |
| MACD | 14.99 | Above its signal line | Bullish |
| Stochastic | 83.5 | Near the top of its range | Overbought |
| ADX (14) | 36.2 | Trending up | |
| Williams %R | -19.1 | Oversold below −80, overbought above −20 | Overbought |
| CCI (20) | 130.5 | Oversold below −100, overbought above 100 | Overbought |
| Rate of change | +15.5% | Change over 10 sessions | Bullish |
| ATR (14) | $13.79 | Typical daily range, 5.5% of price |
What happened before
See how BIIB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How BIIB has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
Whale Options Flow
90DNo whale options trades in BIIB in the last 90 days.
Dark Pool
30DBIIB Institutional Ownership
Full report →- ▲496 buying vs 407 selling
- ▼Held by funds -2.0 pts
- ▲Funds holding +11
- ●Superinvestors: 2 added, 2 cut
- ▼Put/call 0.48 to 0.77
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 1,056 | 1,045 | +1.1% |
| In funds' top 10 | 13 | 9 | +44.4% |
| Held by funds | 94.8% | 96.8% | −2.0 pts |
| New / increased | 91 / 405 | 111 / 425 | −7.5% |
| Reduced / sold out | 337 / 70 | 292 / 84 | +8.2% |
| Put/call ratio | 0.77 | 0.48 | +61.5% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
BIIB Stock Buybacks
See all S&P 500 buybacks →From the company's 10-Q filed Oct 28, 2026. Quarters are the company's own fiscal quarters. Yield and % of value use the latest close. Buybacks are not a forecast: in our testing, the biggest buyers did about the same as the average S&P 500 stock.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BIIB is in one of them and how their past BIIB trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered BIIB in an article yet. Here's the latest on the wider market.
BIIB Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Maria Elvira SalazarR | Sell | $1K – $15K | Sep 24, 2026 | Oct 8, 2026 | 14 d |
| Ro KhannaD · CA | Sell | $1K – $15K | Sep 11, 2026 | Oct 7, 2026 | 26 d |
| Ro KhannaD · CA | Buy | $1K – $15K | Sep 4, 2026 | Oct 7, 2026 | 33 d |
| Kevin HernR · OK | Sell | $1K – $15K | Aug 18, 2026 | Sep 1, 2026 | 14 d |
| Alan ArmstrongHouse | Buy | $1K – $15K | Mar 27, 2026 | Jul 21, 2026 | 116 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Biogen
Biogen is a biopharmaceutical company based in Cambridge, Massachusetts. It discovers, develops and sells medicines for serious and complex diseases, with a focus on neurology, specialized immunology and rare diseases. Its products include treatments for multiple sclerosis, spinal muscular atrophy, Friedreich's ataxia and ALS, along with biosimilars of widely used biologic drugs. Its customers include patients and healthcare providers, and it also works with partners such as Eisai and Genentech on other medicines.
- Headquarters
- Cambridge, MA
- Founded
- 1978
- Website
- biogen.com ↗









